News Akoya Biosciences, Inc.

Equities

AKYA

US00974H1041

Market Closed - Nasdaq Other stock markets 01:30:00 16/05/2024 am IST			5-day change	1st Jan Change
2.79 ^USD	-3.79%		-32.12%	-42.83%

15/05	Piper Sandler Cuts Akoya Biosciences Price Target to $6 From $8, Maintains Overweight Rating	MT
14/05	Top Midday Decliners	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Piper Sandler Cuts Akoya Biosciences Price Target to $6 From $8, Maintains Overweight Rating	15/05	MT
Top Midday Decliners	14/05	MT
Top Premarket Decliners	14/05	MT
Exchange-Traded Funds Mixed, Equity Futures Higher Pre-Bell Tuesday Ahead of Powell Speech	14/05	MT
Akoya Biosciences Sinks Over 30% in Late-Hours Activity Monday as Q1 Sales Miss Capital IQ Estimate	14/05	MT
Transcript : Akoya Biosciences, Inc., Q1 2024 Earnings Call, May 13, 2024	14/05
Akoya: Q1 Earnings Snapshot	14/05	AQ
Earnings Flash (AKYA) AKOYA BIOSCIENCES Reports Q1 Revenue $18.4M, vs. Street Est of $24.3M	14/05	MT
Akoya Biosciences Reports First Quarter 2024 Financial Results	14/05	GL
Akoya Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients	09/05	GL
Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients	09/05	AQ
Akoya Biosciences, Inc. and NeraCare Enters into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients	09/05	CI
Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts	06/05	GL
Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts	06/05	AQ
Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts	06/05	CI
Akoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows	02/05	GL
Akoya Biosciences and Shanghai KR Pharmtech Announces Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows	02/05	CI
Akoya to Report First Quarter 2024 Financial Results on May 13th, 2024	23/04	GL
Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale	05/04	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Akoya Biosciences, Inc.

Equities

AKYA

US00974H1041

Summary

Filters